China’s AI Sector Pushes to Close U.S. Tech Gap Amid Chipmaking Challenges 
Nvidia Appoints Former Google Executive Alison Wagonfeld as First Chief Marketing Officer 
Johnson & Johnson Secures Tariff Exemption by Agreeing to Lower Drug Prices in the U.S. 
OpenAI Sets $50 Billion Stock Grant Pool, Boosting Employee Equity and Valuation Outlook 
Vitol to Ship First U.S. Naphtha Cargo to Venezuela Under New Oil Supply Deal 
Ford Targets Level 3 Autonomous Driving by 2028 with New EV Platform and AI Innovations 
FCC Exempts Select Foreign-Made Drones From U.S. Import Ban Until 2026 
UBS Upgrades L’Oréal to Buy, Sees Strong Sales Momentum and 20% Upside 
FCC Approves Expansion of SpaceX Starlink Network With 7,500 New Satellites 
Hanwha Ocean Shares Rise on Plans to Expand U.S. Shipbuilding Capacity 
Supreme Court to Hear Cisco Appeal on Alien Tort Statute and Human Rights Liability 
Stellantis to End Plug-In Hybrid Sales in the U.S. as Demand Shifts Toward Traditional Hybrids 
SK Hynix Shares Hit Record High as AI Memory Demand Fuels Semiconductor Rally 
Boeing 737 MAX 10 Advances in FAA Testing as Certification Delays Continue 
FTC Blocks Edwards Lifesciences’ JenaValve Acquisition in Major Antitrust Ruling 
xAI Cash Burn Highlights the High Cost of Competing in Generative AI 
Trump Calls for 10% Credit Card Interest Rate Cap Starting 2026 
NEWARK, Calif., March 16, 2017 -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company developing therapies to treat specialty and orphan diseases with high unmet medical need, today announced that it will host a conference call and live audio webcast on Thursday, March 23 at 4:30 p.m. Eastern Time to discuss fourth quarter and full year 2016 financial results and provide a business update.
Conference Call Details
To access the live conference call, please dial 877-407-0784 from the U.S. and Canada, or 201-689-8560 internationally, Conference ID# 13656344. To access the live and subsequently archived webcast of the conference call, go to the Investors section of the company's website at http://ir.cymabay.com/events.
About CymaBay
CymaBay Therapeutics, Inc. (CBAY) is a clinical-stage biopharmaceutical company focused on developing therapies to treat specialty and orphan diseases with high unmet medical need. Seladelpar is a potent, selective, orally active PPARδ agonist. A Phase 2 study of seladelpar in patients with mixed dyslipidemia established that it has an anti-atherogenic lipid profile. CymaBay has completed Phase 2 studies for seladelpar in subjects with primary biliary cholangitis and homozygous familial hypercholesterolemia, establishing proof-of-concept in both indications. Arhalofenate is a potential Urate-Lowering Anti-Flare Therapy that has completed five Phase 2 studies in subjects with gout. Arhalofenate has been found to reduce painful flares in joints while at the same time lowering serum uric acid by promoting excretion of uric acid by the kidney. This dual action addresses both the signs and symptoms of gout while managing the underlying pathophysiology of hyperuricemia. Arhalofenate has been licensed in the U.S. to Kowa Pharmaceuticals America, Inc. CymaBay retains full development and commercialization rights for arhalofenate outside the U.S.
For additional Information about CymaBay visit www.cymabay.com.
Contact: Sujal Shah CymaBay Therapeutics, Inc. (510) 293-8800 [email protected] Hans Vitzthum LifeSci Advisors, LLC 212-915-2568 [email protected]
